Trial Profile
Infliximab for the prevention of recurrent Crohn's disease after surgery
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 09 Sep 2016 Status changed from active, no longer recruiting to completed.
- 17 Jun 2011 Tolerability results published in Digestive Diseases and Sciences.
- 10 Oct 2009 New trial record.